Get in Touch
ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.
ERG delivers end-to-end operational excellence for early-phase clinical development, combining advanced medical expertise with state-of-the-art specialized units. Our custom-designed clinical pharmacology research units feature up to 150-bed capacities and specialized dormitories engineered to support intensive overnight stays lasting 60 or more days. By unifying standardized data collection policies across our entire site network, we confidently minimize environmental variance and harmonize critical data. ERG’s early-phase capabilities span an extensive range of specialized study designs and procedures.
Phase I trials conducted across the ERG network
Active normal healthy volunteers (NHV) meticulously maintained in our database
Combined specialized renal and hepatic clinical pharmacology studies completed (160 renal insufficiency and 140 hepatic impairment studies)
As a specialized leader in early-phase trial design, ERG integrates cutting-edge biomarker testing and rigid cardiac safety parameters into early clinical evaluation to support personalized medicine. Our highly trained clinical staff operates within custom environments where external "noise"—such as temperature, humidity, and acoustic levels—is strictly managed to eliminate data variation. Whether executing sophisticated neuropharmacologic challenges, APOE genetic testing, or intricate crossover TQT studies, ERG provides the precise clinical environment necessary to confidently detect early safety and efficacy signals.
Pharmaceutical sponsors navigating mandatory FDA pharmacokinetic (PK) guidelines trust ERG's world-class clinical pharmacology teams. Originally trained by world-renowned experts, our clinical veterans have successfully guided thousands of trials through complex organ impairment protocols. We possess deep experience managing specialized populations, from mild and moderate impairments to severe cases—including end-stage renal disease (ESRD) requiring active dialysis collaboration—as well as hepatic impairment classifications spanning NASH and Child-Pugh classes A, B, and C.
Swift enrollment is foundational to ERG’s early-phase execution, routinely taking just weeks from contract execution to First Patient In (FPI). Beyond our healthy volunteer database, ERG possesses an expansive centralized network of over 215,000 specialized patients. Through established, close-working relationships with local dialysis centers, hepatologists, and key medical specialists, we can pinpoint, screen, and randomize highly specific subpopulations. This targeted recruitment power ensures that even the most stringent inclusion and exclusion criteria for complex early-phase cohorts are met efficiently and on schedule.
ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.
